Dr. Baliga's Internal Medicine Podcasts

⚕️ "If you want to understand the health of a population, look at the air they breathe, the water they drink, and the places where they live."   More than 2,400 years ago, Hippocrates transformed medicine by arguing that disease had natural—not supernatural—causes. His emphasis on clinical observation, ethics, prognosis, professionalism, and compassionate care laid the foundation for modern medicine.   The Hippocratic Oath remains one of the most enduring ethical pledges in human history.

A fascinating Lancet RCT shows once-weekly semaglutide may redefine alcohol use disorder treatment.

What does it take to be remembered for 3,000 years?

❤️ New in Circulation: the 2026 AHA Dietary Guidance to Improve Cardiovascular Health distills prevention into 9 elegant features—maintain healthy weight, emphasize vegetables/fruits, choose whole grains, favor healthier proteins and unsaturated fats, minimize ultraprocessed foods, added sugars, and sodium, and avoid starting alcohol for health. Food, here, is not garnish; it is strategy.

Can AI think like a physician?

A quiet revolution in tuberculosis diagnostics is here.

A meal may be more than nutrition—it may be immunotherapy.

BP Lowering in CKD: Consistent. Comprehensive. Compelling.

⚡

A fascinating Science (2026) study reveals why the heart is remarkably resistant to cancer. Mechanical load—through contraction and pressure—suppresses tumor proliferation via epigenetic remodeling.  Unloading the heart doubled cancer cell proliferation, while load reduced histone methylation and chromatin compaction through Nesprin-2–mediated mechanotransduction. A striking paradigm: the beating heart is not just a pump—but a biomechanical tumor suppressor.

A simple idea, executed elegantly.   In the NEJM TRIDENT trial, a single low-dose triple antihypertensive pill reduced recurrent stroke after intracerebral hemorrhage (HR 0.61) and improved BP control (50% vs 26%).   Yet, only half reached target—reminding us that pills alone don't solve therapeutic inertia.   The message is clear: simplify treatment, intensify targets, and build systems that ensure control.   One pill helps. Systems save lives.

A pivotal JAMA randomized trial introduces an epigenetic twist to frontline therapy in high-risk DLBCL. Adding tucidinostat (HDAC inhibitor) to R-CHOP improved event-free survival (HR 0.72, P=0.02) and increased complete response rates (73% vs 62%) in MYC/BCL2 double-expressor lymphoma. Toxicity was higher but manageable.   A quiet but meaningful shift—targeting biology, not just burden.   #DLBCL #Lymphoma #Oncology #PrecisionMedicine #JAMA #ClinicalTrials

A pragmatic Lancet RCT (SCOUT) reshapes UTI management. In 768 women, nitrofurantoin achieved the highest clinical resolution at day 7 (74%) vs single-dose fosfomycin (59%), with a significant 15.5% absolute difference. Pivmecillinam and two-dose fosfomycin performed intermediately. Adverse events were mild across groups.   The message is clear: convenience may cost efficacy. Short-course regimens—especially nitrofurantoin—should be preferred over single-dose fosfomycin. A timely reminder that in antimicrobial stewardship, simplicity must not trump success

A large nationwide cohort study in JAMA compared amoxicillin-clavulanate vs amoxicillin for acute sinusitis in >500,000 adults. Treatment failure was low (~3%) with no significant difference between groups (RR 0.96). However, broader-spectrum therapy increased secondary infections, including yeast and C. difficile.   The message is clear: narrow-spectrum amoxicillin remains a rational first-line choice for uncomplicated sinusitis—balancing efficacy, safety, and stewardship.   Sometimes, the quiet drug wins the loud debate.

A quiet revolution in medicine began not in a laboratory—but in a dialogue.

A thoughtful, practice-shaping study in NEJM explores a long-standing clinical dilemma: can we truly move the needle in post-thrombotic syndrome?   The C-TRACT trial shows that endovascular therapy (iliac-vein stenting) significantly improves symptom burden and quality of life in patients with moderate–severe disease—measured rigorously using VCSS, VEINES-QOL, and SF-36. The magnitude of benefit is clinically meaningful.   But every intervention casts a shadow.  

A landmark study in the New England Journal of Medicine shows that hypertension control is no longer just about prescribing medications—it's about systems, teams, and sustained engagement.

Sex hormones shape cardiovascular risk in subtle yet powerful ways. From estrogen-driven changes in coagulation to formulation-specific differences in VTE risk, the nuance matters. Transdermal estradiol offers a safer path, while ethinyl estradiol reminds us that dose and route are destiny. The key is not avoidance—but precision: matching therapy to individual risk.   Three takeaways: • Formulation matters • First year matters • Patient factors matter   #Cardiology #Thrombosis #PrecisionMedicine #HormoneTherapy

  A landmark JAMA study on transcatheter tricuspid valve replacement (TTVR) offers compelling real-world evidence

  A quiet shift, yet a profound one.

What if the roots of modern surgery were written over 2,000 years ago?

A fascinating step forward in Nature—where immunology meets cardiology.

Why do GLP-1 therapies transform some patients—and barely move the needle in others?

Master athletes challenge one of medicine's most elegant assumptions: that fitness always protects.   In the Journal of the American College of Cardiology (JACC) consensus statement on athletes with abnormal cardiovascular findings, a paradox emerges—higher fitness, yet distinct patterns of risk: atrial fibrillation, coronary calcium, myocardial fibrosis.   The lesson is not to discourage exercise—but to refine our lens.   For the clinician: risk stratification must be individualized. For the athlete: performance and prudence must coexist.  

A compelling study in PLOS Medicine: sustained moderate-to-vigorous physical activity across midlife is associated with a ~50% reduction in all-cause mortality in women (target trial emulation). Not intensity, not intermittence—consistency is the signal. For clinicians, the prescription is enduring: move often, move steadily, move for life.

The origins of medicine are not merely scientific—they are deeply philosophical. In our Great Doctors Series, we begin with Dhanvantari, the divine physician of Ayurveda, emerging from myth into method. From the Ocean of Milk to the clinics of today, this episode explores how healing began as a sacred science. For students and physicians alike, it is a reminder that medicine is not just practiced—it is inherited, refined, and reimagined across centuries.

A fascinating and somewhat unsettling observation from JACC: Asia: nearly 1 in 4 STEMI patients in New Delhi had no traditional risk factors—no hypertension, diabetes, dyslipidemia, or smoking. Yet outcomes tell a different story. Despite fewer signs of heart failure at presentation, these patients had worse left ventricular dysfunction and identical in-hospital and 1-year mortality compared with those with standard risk factors. This "SMuRF-less paradox" challenges our conventional risk models. It reminds us that absence of risk factors is not absence of risk. We may need to think beyond the usual suspects—toward genetics, inflammation, lipoprotein(a), and healthcare access delays—to truly understand and prevent cardiovascular disease. A humbling lesson: treat aggressively, think broadly, and never be reassured by a "clean" risk profile.

A thoughtful and important JACC State-of-the-Art Review reframes cardiogenic shock not as a single ICU event, but as a longitudinal survivorship journey. The article highlights recovery, remission, native heart survival, PICS, HF GDMT optimization, and the need for structured multidisciplinary postshock clinics focused on function, cognition, quality of life, and recurrent risk after discharge. A timely call to move from rescue alone to rescue plus recovery.

A landmark 10-year follow-up of the HOST-EXAM trial published in The Lancet challenges a century-old assumption: aspirin may no longer be the default for lifelong secondary prevention after PCI.   Clopidogrel demonstrated a sustained reduction in ischemic and bleeding events (HR 0.86, p=0.005), with benefits that accumulated over time—yet without a mortality difference.   The implication is subtle but profound: we may be witnessing the quiet reshaping of antiplatelet strategy.   In cardiology, tradition often lingers—but data, eventually, prevails.

The New England Journal of Medicine has now given us randomized trial evidence for a question long guided more by extrapolation than by direct proof: in patients with established atherosclerotic cardiovascular disease, targeting LDL cholesterol to

New in Circulation: the 2026 AHA Dietary Guidance to Improve Cardiovascular Health distills prevention into 9 elegant features—maintain healthy weight, emphasize vegetables/fruits, choose whole grains, favor healthier proteins and unsaturated fats, minimize ultraprocessed foods, added sugars, and sodium, and avoid starting alcohol for health. Food, here, is not garnish; it is strategy.